South Africa has technical capabilities to produce vaccines as the country battles with the COVID-19 resurgence.

According to the Higher Education and Training Minister, Dr Blade Nzimande, the threat of future pandemics, has propelled the country’s ability to develop and manufacture vaccines locally into the spotlight.

“Why can’t we produce in South Africa because we’ve produced other vaccines, with the scientist capacity that we have and infrastructure,” Nzimande asked. 

Nzimande told the media on Monday that the government, through the Department of Science and Innovation (DSI), owns a 47.5% stake in Biovac, a biopharmaceutical company.

“The company has over the years developed the capability to manufacture vaccines,” he said.

Last year, the Minister launched an initiative, which sees Biovac manufacturing Hexaxim in partnership with Sanofi.

Hexaxim is the world’s first liquid hexavalent vaccine that protects against diphtheria, tetanus, whooping cough, hepatitis B, Haemophilus influenza type B, and poliomyelitis.

“So, we do have a foundation that we need to build on,” he stressed.

It is also the first World Health Organisation Expanded Programme on Immunisation vaccine to be manufactured in South Africa, which he believes is a strong indication of the technical abilities of South African scientists.

Also, two studies are currently being supported in the area of immunisations. 

“The first is a study on plant-based manufacturing of antibodies for COVID-19, which aims to facilitate the rapid development of SARS-CoV-2 vaccines, therapeutic antibodies and diagnostic reagents utilising various expression platforms for advancing the production of SARS-CoV-2 vaccine candidates and reagents,” he explained.

Meanwhile, the Council for Scientific and Industrial Research (CSIR) has entered into an agreement with Kentucky Biological Products (KBP) for the potential manufacturing of the antigen of their vaccine and expressed interest in testing their vaccine in South Africa.

The second is a ChAdOx1-nCOV-19 vaccine trial, in partnership with the department, South African Medical Research Council and the University of the Witwatersrand.

The study is aimed at assessing the safety, immunogenicity and efficacy of a COVID-19 vaccine candidate (ChAdOx1 SARS-CoV-2) in South African adults living without HIV.

“This is part of an international study aimed at finding a vaccine that will prevent infection by the virus that causes COVID-19, but also assessing whether the vaccines will be effective in local settings.”

In addition, the vaccine developed at the Oxford University Jenner Institute, in collaboration with AstraZeneca is currently being trialled in a number of countries, including South Africa.

“Preliminary results indicate that this vaccine could reduce virus transmission based on an observed reduction in asymptomatic infections.”

The vaccine is at least 62% effective when given in two full-strength doses, compared to the 94% efficacy achieved by Pfizer and Moderna candidate vaccines, he said.

“Of the few vaccines approved globally, the Oxford vaccine, while not as effective as the Pfizer and Moderna vaccines have been touted as the most suitable for developing countries due to its cost, and because it is comparatively easy to transport, store and distribute.”

Total page visits: 135 Visits today: 2 Total site visits: 283361

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

error: Content is protected